Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0AZ8C
|
||||
Former ID |
DNC001331
|
||||
Drug Name |
Silymarin
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Phase 4 | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C25H22O10
|
||||
Canonical SMILES |
COC1=C(C=CC(=C1)C2C(OC3=C(O2)C=C(C=C3)C4C(C(=O)C5=C(C=C<br />(C=C5O4)O)O)O)CO)O
|
||||
InChI |
1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23?,24+,25-/m0/s1
|
||||
InChIKey |
SEBFKMXJBCUCAI-VGHNRKBZSA-N
|
||||
CAS Number |
CAS 22888-70-6
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
SuperDrug ATC ID |
A05BA03
|
||||
SuperDrug CAS ID |
cas=022888706
|
||||
Target and Pathway | |||||
Target(s) | Arachidonate 5-lipoxygenase | Target Info | Inhibitor | [2] | |
BioCyc Pathway | Aspirin-triggered lipoxin biosynthesis | ||||
Resolvin D biosynthesis | |||||
Leukotriene biosynthesis | |||||
Lipoxin biosynthesis | |||||
Aspirin triggered resolvin D biosynthesis | |||||
Aspirin triggered resolvin E biosynthesis | |||||
KEGG Pathway | Arachidonic acid metabolism | ||||
Metabolic pathways | |||||
Serotonergic synapse | |||||
Ovarian steroidogenesis | |||||
Toxoplasmosis | |||||
NetPath Pathway | IL4 Signaling Pathway | ||||
PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
WikiPathways | Vitamin D Receptor Pathway | ||||
Arachidonic acid metabolism | |||||
Eicosanoid Synthesis | |||||
Selenium Micronutrient Network | |||||
References | |||||
REF 1 | ClinicalTrials.gov (NCT00412763) Efficacy of Silymarin for Acute Hepatitis. U.S. National Institutes of Health. | ||||
REF 2 | Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine. 2000 Mar;7(1):21-4. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.